Document is current
Any future updates will be listed below
-
Authors
Chiou, Shene https://orcid.org/0000-0003-1295-2183
Horne, Christopher R. https://orcid.org/0000-0003-1318-514X
Patel, Komal M.
Preaudet, Adele
Rickard, James A.
Young, Samuel N. https://orcid.org/0009-0001-6543-1851
Jois, Asha
Garnish, Sarah E.
Hempel, Anne
Hall, Cathrine
Hildebrand, Joanne M. https://orcid.org/0000-0002-1456-2042
Kueh, Andrew J.
Silke, John https://orcid.org/0000-0002-7611-5774
Putoczki, Tracy L.
Hawkins, Edwin D. https://orcid.org/0000-0002-3686-8261
Samson, Andre L. https://orcid.org/0000-0002-0637-2716
Murphy, James M. https://orcid.org/0000-0003-0195-3949
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1172929)
Department of Health | National Health and Medical Research Council (2034104)
Department of Health | National Health and Medical Research Council (2034044)
Department of Health | National Health and Medical Research Council (2008652)
Department of Health | National Health and Medical Research Council (2002965)
Department of Health | National Health and Medical Research Council (1195038)
Sylvia and Charles Viertel Charitable Foundation
- License Information
-
More Information
Article History
Received: 24 April 2025
Revised: 31 December 2025
Accepted: 21 January 2026
First Online: 3 February 2026
Competing interests
: KMP, CRH, SNY, AH, JMH, JS, ALS and JMM contribute to or have contributed to a project developing necroptosis inhibitors in collaboration with Anaxis Pharma. TLP is cofounder and shareholder in Nelcanen Therapeutics. The other authors declare no competing interests.
: All experiments were approved by the WEHI Animal Ethics Committee following the Prevention of Cruelty to Animals Act (1996) and the Australian National Health and Medical Research Council Code of Practice for the Care and Use of Animals for Scientific Purposes (1997).
